GenEditBio closes angel and pre-A rounds of funding to develop gene-editing tools
GenEditBio Limited (“GenEditBio”), which was established in 2021 and has laboratories and offices in Beijing, Hong Kong and Boston, has raised tens of millions of U.S. dollars in angel and series pre-A funding to develop next-generation gene-editing tools and advance its pipelines.
This financing round was generously supported by Qiming Venture Partners and Fangyuan Capital. GenEditBio is developing next-generation CRISPR tools to make gene editing more efficient and precise, and to minimize off-target effects.
The scientific founder of GenEditBio, Dr Zongli Zheng, once worked with J. Keith Joung, a top-tier expert in designing gene-editing tools and a co-founder of Editas Medicine, Beam Therapeutics, Verve Therapeutics, Chroma Medicine and Pairwise Plants, co-developed a new off-target assessment method called Genome-wide and Unbiased Identification of DSBs Enabled by sequencing (GUIDE-seq) during his training at Harvard Medical School.
Dr. Zheng has over ten years of experience in the field of gene editing. GUIDE-Seq is currently one of the most widely used methods. He has several world-leading research achievements in the areas of off-target assessment, high-fidelity nucleases and next-generation editing tools. He has published many relevant research articles in top journals. The core members of GenEditBio are professionals with academic backgrounds in gene editing technology and extensive international experience in innovative drug research and business development.